Pub Date : 2016-11-08DOI: 10.5455/BCP.20160220032354
S. Taşkıran, A. Tufan, B. Semerci
ABSTRACTTic disorders may cause impairment both by themselves and associated comorbidities. Medications for tic disorders are indicated when tics are moderate/severe causing severe impairment and in presence of comorbid disorders responsive to medications. Duration of improvement is still not known as the literature lacks prospective studies with a long follow-up period. This case series aims to report management of tic disorders with aripiprazole in patients with different ages. Here, we describe 8 cases with complex motor tic disorder or Tourette's Disorder in which aripiprazole was used. The ages of patients were varied, from 9 to 57 years. Mean follow-up was 19.6 weeks. Mean dose of aripiprazole for pediatric patients was 15.4 mg/ day while it was 12.5 mg/ day for adult patients. All patients benefited from treatment with aripiprazole in the long term. Our results should be supported with controlled studies.
{"title":"Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series","authors":"S. Taşkıran, A. Tufan, B. Semerci","doi":"10.5455/BCP.20160220032354","DOIUrl":"https://doi.org/10.5455/BCP.20160220032354","url":null,"abstract":"ABSTRACTTic disorders may cause impairment both by themselves and associated comorbidities. Medications for tic disorders are indicated when tics are moderate/severe causing severe impairment and in presence of comorbid disorders responsive to medications. Duration of improvement is still not known as the literature lacks prospective studies with a long follow-up period. This case series aims to report management of tic disorders with aripiprazole in patients with different ages. Here, we describe 8 cases with complex motor tic disorder or Tourette's Disorder in which aripiprazole was used. The ages of patients were varied, from 9 to 57 years. Mean follow-up was 19.6 weeks. Mean dose of aripiprazole for pediatric patients was 15.4 mg/ day while it was 12.5 mg/ day for adult patients. All patients benefited from treatment with aripiprazole in the long term. Our results should be supported with controlled studies.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89213016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151101022909
Selahattin Bölek, I. Yargıç, O. Ekinci
ABSTRACTObjective: Abstinance is not the only goal of the current drug addiction treatment modalities. New modalities focus rather on improvement in physical and mental health, personal and social functionality. It has been found that opioid maintanence treatment reduces the rates of illicit drug use, crime and sexual transmitted diseases in addition to increasing psychiatric, somatic and social functionality. In this study, we examined the effects of Buprenorphine/Naloxane (BN) maintenance treatment on substance abuse, quality of life and functionality.Method: The sample contained 50 opiate-dependent individuals who were hospitalized at the inpatient psychiatric unit for opioid detoxification and then followed at the addiction outpatient clinic of Istanbul University, Faculty of Medicine after their discharge from the hospital. The first interview was conducted at the inpatient unit and other interviews were conducted at the addiction outpatient clinic. The Addiction Severity Index and The Short-Form 36 ...
{"title":"The effects of Buprenorphine/Naloxane Maintenance Treatment on the Quality of Life, Substance Use and Functionality in Opiate Dependence: A Follow-Up Study","authors":"Selahattin Bölek, I. Yargıç, O. Ekinci","doi":"10.5455/BCP.20151101022909","DOIUrl":"https://doi.org/10.5455/BCP.20151101022909","url":null,"abstract":"ABSTRACTObjective: Abstinance is not the only goal of the current drug addiction treatment modalities. New modalities focus rather on improvement in physical and mental health, personal and social functionality. It has been found that opioid maintanence treatment reduces the rates of illicit drug use, crime and sexual transmitted diseases in addition to increasing psychiatric, somatic and social functionality. In this study, we examined the effects of Buprenorphine/Naloxane (BN) maintenance treatment on substance abuse, quality of life and functionality.Method: The sample contained 50 opiate-dependent individuals who were hospitalized at the inpatient psychiatric unit for opioid detoxification and then followed at the addiction outpatient clinic of Istanbul University, Faculty of Medicine after their discharge from the hospital. The first interview was conducted at the inpatient unit and other interviews were conducted at the addiction outpatient clinic. The Addiction Severity Index and The Short-Form 36 ...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76642448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151013010412
İlyas Kaya, F. Suleyman, M. Coskun
ABS TRACT: Cyproheptadine-induced obsessive-compulsive symptoms in a preschool child Cyproheptadine is a first-generation antihistamine with additional anticholinergic, antiserotonergic, and local-anesthetic properties. It has been shown effective as an appetite stimulant in the treatment of young children with feeding difficulties and poor growth with or without medical illness. Adverse reactions to cyproheptadine may include sedation, confusion, hallucinations, convulsions, hypotension, palpitations, and tachycardia. Despite cyproheptadine may cause neuropsychiatric side effects, a review of literature showed that there is no report of cyproheptadine induced obsessive compulsive symptoms. Here, we present a preschool girl with sexual and religious obsessions emerged after using cyproheptadine as an appetite stimulant for one week.
{"title":"Cyproheptadine-Induced Obsessive-Compulsive Symptoms in a Preschool Child","authors":"İlyas Kaya, F. Suleyman, M. Coskun","doi":"10.5455/BCP.20151013010412","DOIUrl":"https://doi.org/10.5455/BCP.20151013010412","url":null,"abstract":"ABS TRACT: Cyproheptadine-induced obsessive-compulsive symptoms in a preschool child Cyproheptadine is a first-generation antihistamine with additional anticholinergic, antiserotonergic, and local-anesthetic properties. It has been shown effective as an appetite stimulant in the treatment of young children with feeding difficulties and poor growth with or without medical illness. Adverse reactions to cyproheptadine may include sedation, confusion, hallucinations, convulsions, hypotension, palpitations, and tachycardia. Despite cyproheptadine may cause neuropsychiatric side effects, a review of literature showed that there is no report of cyproheptadine induced obsessive compulsive symptoms. Here, we present a preschool girl with sexual and religious obsessions emerged after using cyproheptadine as an appetite stimulant for one week.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90189387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20160520092044
C. Şahin, S. Dursun, M. Cetin, F. Aricioglu
ABSTRACTMajor Depressive Disorder (MDD) is a serious mental health problem that leads to patients' disability and has huge impact on social and economic burden to society. The current available medications for the treatment of depression are mainly targeted on enhancing monoamine neurotransmission. However, antidepressant treatments are still lacking high efficacy in many cases which is associated with low treatment response and remission rates. However, the latest knowledge regarding the pathophysiology of depression indicates that depression is developed by highly complex and integrated mechanisms in which monoaminergic deficiency could only be part of. The paradigm is now shifting from monoaminergic hypothesis to significance of other novel mechanisms that could possibly play substantial role for the development of depression in a highly inter-related manner. In fact, neuroinflammation, amongst other mechanisms does seem to be a key pathological component by having impact on certain pathway pathologies...
{"title":"The Neuroinflammation Perspective of Depression: Reuniting the Outstanding Mechanisms of the Pathophysiology","authors":"C. Şahin, S. Dursun, M. Cetin, F. Aricioglu","doi":"10.5455/BCP.20160520092044","DOIUrl":"https://doi.org/10.5455/BCP.20160520092044","url":null,"abstract":"ABSTRACTMajor Depressive Disorder (MDD) is a serious mental health problem that leads to patients' disability and has huge impact on social and economic burden to society. The current available medications for the treatment of depression are mainly targeted on enhancing monoamine neurotransmission. However, antidepressant treatments are still lacking high efficacy in many cases which is associated with low treatment response and remission rates. However, the latest knowledge regarding the pathophysiology of depression indicates that depression is developed by highly complex and integrated mechanisms in which monoaminergic deficiency could only be part of. The paradigm is now shifting from monoaminergic hypothesis to significance of other novel mechanisms that could possibly play substantial role for the development of depression in a highly inter-related manner. In fact, neuroinflammation, amongst other mechanisms does seem to be a key pathological component by having impact on certain pathway pathologies...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86511014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20160325085828
O. Yanartaş, M. Sunbul, E. Durmuş, T. Kıvrak, Zeynep Şenkal, Nilufer Subasi, Gulhan Karaer, Serhat Ergün, I. Sari, K. Sayar
ABSTRACTObjective: Depression and anxiety are associated with both subclinical and clinical cardiovascular disease. Endothelial dysfunction, atherosclerosis, and inflammation are some of the underlying mechanisms. Pulse wave velocity (PWV) and augmentation index (AIx) are noninvasive markers for evaluation of arterial stiffness. The aim of this study was to examine the association between arterial stiffness parameters and depression/anxiety scores in depressive patients undergoing psychiatric treatment.Methods: The study population consisted of 30 patients with depression undergoing psychiatric treatment at least 4 weeks, and 25 age and gender matched healthy controls. Depression and anxiety were assessed by self-reported scales, including the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). Measurements of arterial stiffness parameters were performed by using a Mobil-O-Graph arteriograph system, which detects signals from the brachial artery.Results: Baseline characteristics and clinical...
{"title":"Severity of Depression and Anxiety Symptoms is Associated with Increased Arterial Stiffness in Depressive Disorder Patients Undergoing Psychiatric Treatment","authors":"O. Yanartaş, M. Sunbul, E. Durmuş, T. Kıvrak, Zeynep Şenkal, Nilufer Subasi, Gulhan Karaer, Serhat Ergün, I. Sari, K. Sayar","doi":"10.5455/BCP.20160325085828","DOIUrl":"https://doi.org/10.5455/BCP.20160325085828","url":null,"abstract":"ABSTRACTObjective: Depression and anxiety are associated with both subclinical and clinical cardiovascular disease. Endothelial dysfunction, atherosclerosis, and inflammation are some of the underlying mechanisms. Pulse wave velocity (PWV) and augmentation index (AIx) are noninvasive markers for evaluation of arterial stiffness. The aim of this study was to examine the association between arterial stiffness parameters and depression/anxiety scores in depressive patients undergoing psychiatric treatment.Methods: The study population consisted of 30 patients with depression undergoing psychiatric treatment at least 4 weeks, and 25 age and gender matched healthy controls. Depression and anxiety were assessed by self-reported scales, including the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). Measurements of arterial stiffness parameters were performed by using a Mobil-O-Graph arteriograph system, which detects signals from the brachial artery.Results: Baseline characteristics and clinical...","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87313457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20160323105909
Ö. Öztürk, O. Basay, B. Basay, H. Alacam, Ahmet Buber, B. Kaptanoǧlu, Y. Enli, Mustafa Doğan, Omer Faruk Tuncer, A. Kardeşler
Objective: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments in social interactions and behavioral problems. Various genetic and environmental factors, including oxidative stress, are claimed to play a role in the etiopathogenesis of ASD. In this study, we aimed to examine the status of oxidative metabolism in ASD and the association between oxidative parameters and ASD symptom severity and subtype of ASD. Method: Thirty-three children and adolescents diagnosed with ASD (16 children diagnosed with autistic disorder, 13 children with pervasive developmental disorder not otherwise specified, and 4 children with Asperger syndrome) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and 28 healthy controls, aged 2-17 years, were recruited in this study. Total oxidant status (TOS) and total antioxidant status (TAS) were evaluated using Rel Assay Kit in children and adolescents. The oxidative stress index (OSI) was calculated by dividing the TOS values by the TAS values. Autistic symptoms for these patients were scored on the Childhood Autism Rating Scale (CARS). Results: In patients with ASD, TAS was statistically significantly lower and OSI statistically significantly higher than in healthy controls. There were no statistically significant differences in TOS between the ASD and control groups. There were no statistically significant differences between the subtypes of ASD in terms of oxidative stress parameters. In addition, TAS, TOS, and OSI values did not differ statistically significantly between the patients’ CARS groups, and were not associated with the CARS scores of the patients. Conclusion: Our findings suggest that oxidative imbalance is present in ASD and that oxidative stress may play a role in the etiopathogenesis of ASD. Therefore, it is suggested that antioxidants may have beneficial effects on ASD and may be a new therapeutic target in treating ASD.
{"title":"Oxidative imbalance in children and adolescents with autism spectrum disorder","authors":"Ö. Öztürk, O. Basay, B. Basay, H. Alacam, Ahmet Buber, B. Kaptanoǧlu, Y. Enli, Mustafa Doğan, Omer Faruk Tuncer, A. Kardeşler","doi":"10.5455/BCP.20160323105909","DOIUrl":"https://doi.org/10.5455/BCP.20160323105909","url":null,"abstract":"Objective: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments in social interactions and behavioral problems. Various genetic and environmental factors, including oxidative stress, are claimed to play a role in the etiopathogenesis of ASD. In this study, we aimed to examine the status of oxidative metabolism in ASD and the association between oxidative parameters and ASD symptom severity and subtype of ASD. \u0000Method: Thirty-three children and adolescents diagnosed with ASD (16 children diagnosed with autistic disorder, 13 children with pervasive developmental disorder not otherwise specified, and 4 children with Asperger syndrome) according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and 28 healthy controls, aged 2-17 years, were recruited in this study. Total oxidant status (TOS) and total antioxidant status (TAS) were evaluated using Rel Assay Kit in children and adolescents. The oxidative stress index (OSI) was calculated by dividing the TOS values by the TAS values. Autistic symptoms for these patients were scored on the Childhood Autism Rating Scale (CARS). \u0000Results: In patients with ASD, TAS was statistically significantly lower and OSI statistically significantly higher than in healthy controls. There were no statistically significant differences in TOS between the ASD and control groups. There were no statistically significant differences between the subtypes of ASD in terms of oxidative stress parameters. In addition, TAS, TOS, and OSI values did not differ statistically significantly between the patients’ CARS groups, and were not associated with the CARS scores of the patients. \u0000Conclusion: Our findings suggest that oxidative imbalance is present in ASD and that oxidative stress may play a role in the etiopathogenesis of ASD. Therefore, it is suggested that antioxidants may have beneficial effects on ASD and may be a new therapeutic target in treating ASD.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85624128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151003061901
I. Belenichev, E. Sokolik, Nina V. Bukhtiarova, S. V. Levich
Objective: One of the primary reactions of the genome in response to stress is different genesis induction of heat shock proteins – HSP. The purpose of this study was to investigate the concentration of heat shock protein (HSP70) and hypoxia-inducible factor (HIF-1) in the brain of rats undergoing chronic prenatal alcoholism in different periods of ischemia and define the role of these proteins in the implementation of neuroprotective effect of Cerebrocurin and Tiocetam. Methods: Experiments were carried out on female rats weighing 150-180 g. All animals were on standard food ration of vivarium, with natural alteration of day and night. Rats were recieved from nursery of «Institute of Pharmacology and Toxicology, Academy of Medical Sciences of Ukraine». All experimental procedures and operative interventions were done in accordance with WMA Statement on Animal Use in Biomedical Research. Rats from the 5th to the 20th day of gestation received ethanol in a dose of 6-8 g/kg/day, control rats – isocalorific sucrose solution. Offspring of alcoholized rats immediately after birth during 25 days were injected intraperitoneally Tiocetam (125 mg/kg), Piracetam (125 mg/kg) and Cerebrocurin (0.06 mg/kg), control rats received saline solution. There were 20 infants in each group. Biochemical studies carried out on brain on 26 days of the experiment, for this purpose the animals were decapitated under anesthesia using Thiopental (30 mg/kg, intraperitoneally). Concentration in the brain tissue and HIF proteins and HSP proteins were determined by Western blot analysis. Results: Study of concentration in brain tissue HIF proteins and HSP-proteins showed that after undergoing prenatal chronic alcoholism there was an observed decrease in concentration of HSP, so HIF-proteins. Course treatment by Cerebrocurin and Tiocetam resulted in statistically significant increased content of HIF and HSP proteins in the brain in comparison with a group of untreated animals. Neuroprotective activity of Cerebrocurin and Tiocetam was observed in reduction of neurological deficit, as evidenced by the statistically significant decrease in the average score on a scale of C.P. McGrow. Cerebrocurin and Tiocetam directly or indirectly can modulate the expression of early response c-fos genes and thus the “run” software adaptation protein synthesis (including HSP and HIF) in neurons with acute cerebral ischemia. Conclusion: Implementation of the neuroprotective effect of Cerebrocurin and Tiocetam revealed apparently their ability to increase the concentration in the brain tissues of HSP-protein.
{"title":"Pharmacological modulation of Heat Shock Protein 70 (HSP70) - dependent mechanisms of endogenous neuroprotection in conditions of prenatal chronic alcoholism by Cerebrocurin and Tiocetam -","authors":"I. Belenichev, E. Sokolik, Nina V. Bukhtiarova, S. V. Levich","doi":"10.5455/BCP.20151003061901","DOIUrl":"https://doi.org/10.5455/BCP.20151003061901","url":null,"abstract":"Objective: One of the primary reactions of the genome in response to stress is different genesis induction of heat shock proteins – HSP. The purpose of this study was to investigate the concentration of heat shock protein (HSP70) and hypoxia-inducible factor (HIF-1) in the brain of rats undergoing chronic prenatal alcoholism in different periods of ischemia and define the role of these proteins in the implementation of neuroprotective effect of Cerebrocurin and Tiocetam. \u0000Methods: Experiments were carried out on female rats weighing 150-180 g. All animals were on standard food ration of vivarium, with natural alteration of day and night. Rats were recieved from nursery of «Institute of Pharmacology and Toxicology, Academy of Medical Sciences of Ukraine». All experimental procedures and operative interventions were done in accordance with WMA Statement on Animal Use in Biomedical Research. Rats from the 5th to the 20th day of gestation received ethanol in a dose of 6-8 g/kg/day, control rats – isocalorific sucrose solution. Offspring of alcoholized rats immediately after birth during 25 days were injected intraperitoneally Tiocetam (125 mg/kg), Piracetam (125 mg/kg) and Cerebrocurin (0.06 mg/kg), control rats received saline solution. There were 20 infants in each group. Biochemical studies carried out on brain on 26 days of the experiment, for this purpose the animals were decapitated under anesthesia using Thiopental (30 mg/kg, intraperitoneally). Concentration in the brain tissue and HIF proteins and HSP proteins were determined by Western blot analysis. \u0000Results: Study of concentration in brain tissue HIF proteins and HSP-proteins showed that after undergoing prenatal chronic alcoholism there was an observed decrease in concentration of HSP, so HIF-proteins. Course treatment by Cerebrocurin and Tiocetam resulted in statistically significant increased content of HIF and HSP proteins in the brain in comparison with a group of untreated animals. Neuroprotective activity of Cerebrocurin and Tiocetam was observed in reduction of neurological deficit, as evidenced by the statistically significant decrease in the average score on a scale of C.P. McGrow. Cerebrocurin and Tiocetam directly or indirectly can modulate the expression of early response c-fos genes and thus the “run” software adaptation protein synthesis (including HSP and HIF) in neurons with acute cerebral ischemia. \u0000Conclusion: Implementation of the neuroprotective effect of Cerebrocurin and Tiocetam revealed apparently their ability to increase the concentration in the brain tissues of HSP-protein.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87061587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20150706034008
S. Pehlivan, R. Fedakar, B. Eren, S. Akyol, F. Eren, N. T. Inanir, Murat Serdar Gürses, M. Ural, S. M. Tagil, K. Demircan
Objective: Recent studies performed in the central nervous system highlight the pathophysiological relevance of A disintegrin-like and metalloproteinase with thrombospondin motifs (ADAMTS) genes and their protein products. The determination of alterations in expression profiles of ADAMTS family genes in Alzheimer’s disease (AD) patients may contribute to the explanation of tissue pathology and also new ideas for remedial approaches for this incurable but preventable disease. Therefore, the goal of this study was to describe and identify the distribution, characteristics, and any changes in the expression, in other words, immunoreactivity, for aggrecanases (ADAMTS4, 5, 9, and 15) proteins in AD brain. Methods: Nine cases that were autopsied in the Council of Forensic Medicine, Bursa Morgue Department in 2013, were selected. All of the cases were sent for autopsy to the institution within 8 hours after death. At autopsy, tissue samples were obtained for histopathological examination of organs for determining the cause of death. Out of these, two cases were diagnosed with AD by neurologists when they were alive. Immunohistochemical staining was performed on the brain slides by using relevant primary and secondary antibodies against aggrecanase proteins. All images were acquired using a X200 objective of a microscope (Olympus BX53) and evaluated by the staining intensity using a semi-quantitative scoring system. Results: ADAMTS4 and 5 were slightly under-expressed in the brains from autopsied AD cases compared to those of control brains and suggested that extracellular matrix (ECM) degradation was not endorsed in AD brain. On the other hand, ADAMTS9 and 15 aggrecanases were not found to be expressed in correspondent brain sections of AD and control cases. Conclusion: The current study demonstrated that some aggrecanases were found to be under-expressed in AD brains. Additional studies in which all ADAMTS enzymes will be studied in terms of mRNA and protein levels are needed to understand the relative contributions of ADAMTS genes and proteins in AD brains.
{"title":"ADAMTS4, 5, 9, and 15 expressions in the autopsied brain of patients with Alzheimer’s disease: a preliminary immunohistochemistry study -","authors":"S. Pehlivan, R. Fedakar, B. Eren, S. Akyol, F. Eren, N. T. Inanir, Murat Serdar Gürses, M. Ural, S. M. Tagil, K. Demircan","doi":"10.5455/BCP.20150706034008","DOIUrl":"https://doi.org/10.5455/BCP.20150706034008","url":null,"abstract":"Objective: Recent studies performed in the central nervous system highlight the pathophysiological relevance of A disintegrin-like and metalloproteinase with thrombospondin motifs (ADAMTS) genes and their protein products. The determination of alterations in expression profiles of ADAMTS family genes in Alzheimer’s disease (AD) patients may contribute to the explanation of tissue pathology and also new ideas for remedial approaches for this incurable but preventable disease. Therefore, the goal of this study was to describe and identify the distribution, characteristics, and any changes in the expression, in other words, immunoreactivity, for aggrecanases (ADAMTS4, 5, 9, and 15) proteins in AD brain. \u0000Methods: Nine cases that were autopsied in the Council of Forensic Medicine, Bursa Morgue Department in 2013, were selected. All of the cases were sent for autopsy to the institution within 8 hours after death. At autopsy, tissue samples were obtained for histopathological examination of organs for determining the cause of death. Out of these, two cases were diagnosed with AD by neurologists when they were alive. Immunohistochemical staining was performed on the brain slides by using relevant primary and secondary antibodies against aggrecanase proteins. All images were acquired using a X200 objective of a microscope (Olympus BX53) and evaluated by the staining intensity using a semi-quantitative scoring system. \u0000Results: ADAMTS4 and 5 were slightly under-expressed in the brains from autopsied AD cases compared to those of control brains and suggested that extracellular matrix (ECM) degradation was not endorsed in AD brain. On the other hand, ADAMTS9 and 15 aggrecanases were not found to be expressed in correspondent brain sections of AD and control cases. \u0000Conclusion: The current study demonstrated that some aggrecanases were found to be under-expressed in AD brains. Additional studies in which all ADAMTS enzymes will be studied in terms of mRNA and protein levels are needed to understand the relative contributions of ADAMTS genes and proteins in AD brains.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85628166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151003060122
Erdem Onder Sonmez, F. Aksoy, N. Kaya, M. Camkurt
To the Editor: Priapism, an uncommon urological emergency, is a pathological, prolonged and painful penile erection, usually unassociated with sexual desire or intercourse 1 . Drug-induced priapism comprises about 30% of the cases and it’s estimated 50% of them occurred with antipsychotic agents 2 . Although typical antipsychotics are often associated with priapism, there are some case reports with clozapine, risperidone, olanzapine, quetiapine, and aripiprazole 3 . Here, we present a case report of dose dependent priapism due to 800 mg/day of amisulpiride. 26 year-old- male patient was admitted to our inpatient clinic with disorganized speech and behavior, and persecutory delusions and was diagnosed as schizophrenia . He was on amisulpiride 200 mg/day treatment for one year. His previous treatments were flupentixol depot, olanzapine, risperidone, and chlorpromazine. He was switched to amisulpiride 1 year ago due to side effect of weight gain. The patient’s physical and neurological examinations, urine-blood drug and substance screening, and labaratory tests were normal. Increasing the dose of Amisulpride 200/ mg per week, a dose of 800 mg/day was attained. In the first day of using 800 mg amisulpride, patient reported to have involuntary, painful erection which lasted about 6 hours. Urology consultation was requested and the urology specialist ruled out other causes and reported that priapism was probably due to amisulpride use. Urology consultant did not mention any other medical condition for priapism. So amisulpride treatment was stopped. We did not observe priapism for 3 days after stopping medication. As we knew that previously, patient was clinically stable with 600 mg/day of amisulpride, we decided to initate amisulpride again. We started at 400 mg/ day dose and increased to 600 mg/day after 3 days. We did not observe priapism with 600 mg/day. This time, we decided not to increase Amisulpride dose to 800 mg/day.
{"title":"Dose Dependent Priapism Induced by Amisulpride Use","authors":"Erdem Onder Sonmez, F. Aksoy, N. Kaya, M. Camkurt","doi":"10.5455/BCP.20151003060122","DOIUrl":"https://doi.org/10.5455/BCP.20151003060122","url":null,"abstract":"To the Editor: Priapism, an uncommon urological emergency, is a pathological, prolonged and painful penile erection, usually unassociated with sexual desire or intercourse 1 . Drug-induced priapism comprises about 30% of the cases and it’s estimated 50% of them occurred with antipsychotic agents 2 . Although typical antipsychotics are often associated with priapism, there are some case reports with clozapine, risperidone, olanzapine, quetiapine, and aripiprazole 3 . Here, we present a case report of dose dependent priapism due to 800 mg/day of amisulpiride. 26 year-old- male patient was admitted to our inpatient clinic with disorganized speech and behavior, and persecutory delusions and was diagnosed as schizophrenia . He was on amisulpiride 200 mg/day treatment for one year. His previous treatments were flupentixol depot, olanzapine, risperidone, and chlorpromazine. He was switched to amisulpiride 1 year ago due to side effect of weight gain. The patient’s physical and neurological examinations, urine-blood drug and substance screening, and labaratory tests were normal. Increasing the dose of Amisulpride 200/ mg per week, a dose of 800 mg/day was attained. In the first day of using 800 mg amisulpride, patient reported to have involuntary, painful erection which lasted about 6 hours. Urology consultation was requested and the urology specialist ruled out other causes and reported that priapism was probably due to amisulpride use. Urology consultant did not mention any other medical condition for priapism. So amisulpride treatment was stopped. We did not observe priapism for 3 days after stopping medication. As we knew that previously, patient was clinically stable with 600 mg/day of amisulpride, we decided to initate amisulpride again. We started at 400 mg/ day dose and increased to 600 mg/day after 3 days. We did not observe priapism with 600 mg/day. This time, we decided not to increase Amisulpride dose to 800 mg/day.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82667946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-08DOI: 10.5455/BCP.20151011110055
S. Demir, M. Bulut, A. Atlı, M. Güneş, M. Kaya, A. Ibiloğlu, Songül Çatı, A. Sır
Objective: Electroconvulsive therapy (ECT) is an efficient and reliable somatic treatment used to treat severe mental disorders. ECT procedure is generally performed by hospitalizing the patient in our country (Turkey). However, there is no obligation to perform ECT by hospitalization, as ECT may be performed without hospitalizing the patient. Outpatient ECT gradually increases during acute and maintenance treatment. Outpatient ECT provides some advantages, such as reduced disruption in social and professional functionality and decrease in treatment costs. Studies that compare acute outpatient ECT and ECT applied after hospitalization are limited. In the present study, we aimed to review clinical characteristics of acute ambulatory ECT and ECT applied by hospitalization comprehensively and retrospectively. Methods: Inpatients and outpatients that received ECT in the Psychiatry Clinic of Dicle University between 2011 and 2014 were enrolled in the present study. Patients’ files between aforementioned years were reviewed retrospectively and data including patient age, gender, diagnosis according to DSM system, hospitalization period, whether ECT was applied, number of ECT sessions, and whether ECT was performed as an inpatient or outpatient procedure were recorded. For the patients who were hospitalized multiple times, each hospitalization was regarded as a different patient and data were assessed independently. For the outpatients who received ECT, all separate ECT sessions were added and ECT count was determined. Those who received maintenance ECT sessions were not included in the outpatient ECT group. Patients who received ECT by acute referral as outpatients were included in this group. Results: Between 2011 and 2014, 904 patients were admitted to the Psychiatry Clinic of Dicle University, Faculty of Medicine , of which 138 received ECT treatment. We also included in the study an additional 38 outpatients who received acute ECT. Inpatients of our clinic in application to ECT were rates of 15.3%. There was no statistically significant difference detected between age, number of ECT sessions applied, diagnosis, and gender of admitted inpatients and outpatients (p>0.05). Conclusions: In our study clinical characteristics of inpatients and outpatients subjects who admitted in order to practiced the ECT were determined to be similar. We believe that an efficient treatment method may be presented to the patients by including acute outpatient ECT more frequently in the treatment plan from physicians.
{"title":"Comparison of Clinical Characteristics of Patients on whom Electroconvulsive Therapy was Applied as Inpatient and Outpatient","authors":"S. Demir, M. Bulut, A. Atlı, M. Güneş, M. Kaya, A. Ibiloğlu, Songül Çatı, A. Sır","doi":"10.5455/BCP.20151011110055","DOIUrl":"https://doi.org/10.5455/BCP.20151011110055","url":null,"abstract":"Objective: Electroconvulsive therapy (ECT) is an efficient and reliable somatic treatment used to treat severe mental disorders. ECT procedure is generally performed by hospitalizing the patient in our country (Turkey). However, there is no obligation to perform ECT by hospitalization, as ECT may be performed without hospitalizing the patient. Outpatient ECT gradually increases during acute and maintenance treatment. Outpatient ECT provides some advantages, such as reduced disruption in social and professional functionality and decrease in treatment costs. Studies that compare acute outpatient ECT and ECT applied after hospitalization are limited. In the present study, we aimed to review clinical characteristics of acute ambulatory ECT and ECT applied by hospitalization comprehensively and retrospectively. \u0000Methods: Inpatients and outpatients that received ECT in the Psychiatry Clinic of Dicle University between 2011 and 2014 were enrolled in the present study. Patients’ files between aforementioned years were reviewed retrospectively and data including patient age, gender, diagnosis according to DSM system, hospitalization period, whether ECT was applied, number of ECT sessions, and whether ECT was performed as an inpatient or outpatient procedure were recorded. For the patients who were hospitalized multiple times, each hospitalization was regarded as a different patient and data were assessed independently. For the outpatients who received ECT, all separate ECT sessions were added and ECT count was determined. Those who received maintenance ECT sessions were not included in the outpatient ECT group. Patients who received ECT by acute referral as outpatients were included in this group. \u0000Results: Between 2011 and 2014, 904 patients were admitted to the Psychiatry Clinic of Dicle University, Faculty of Medicine , of which 138 received ECT treatment. We also included in the study an additional 38 outpatients who received acute ECT. Inpatients of our clinic in application to ECT were rates of 15.3%. There was no statistically significant difference detected between age, number of ECT sessions applied, diagnosis, and gender of admitted inpatients and outpatients (p>0.05). \u0000Conclusions: In our study clinical characteristics of inpatients and outpatients subjects who admitted in order to practiced the ECT were determined to be similar. We believe that an efficient treatment method may be presented to the patients by including acute outpatient ECT more frequently in the treatment plan from physicians.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73018379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：